Zhou et al, transfected the dominant-negative mutant inhibitor of NFκB (IκBm) into an acute lymphoblastic leukaemia (ALL) cell line with constitutive NFκB activation [147]. Here, NFKB1 is linked to acute lymphoblastic leukemia.